Drug Profile
BTP 114
Alternative Names: BTP-114Latest Information Update: 28 Oct 2019
Price :
$50
*
At a glance
- Originator Tarveda Therapeutics
- Developer Placon Therapeutics
- Class Antineoplastics; Drug conjugates; Platinum complexes
- Mechanism of Action DNA cross linking agents
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes - Cancer
Highest Development Phases
- No development reported Solid tumours
Most Recent Events
- 28 Oct 2019 No recent reports of development identified for phase-I development in Solid-tumours in USA (IV)
- 01 Sep 2016 Phase-I clinical trials in Solid tumours in USA (IV) (NCT02950064)
- 01 Feb 2016 BTP 114 is available for licensing as of 27 Jan 2016.